J&J’s new esketamine drug for depression, Spravato, not worth the money or the risk, watchdog says - Philly.com

Submitted by Anonymous (not verified) on Mon, 05/13/2019 - 12:15

J&J’s new esketamine drug for depression, Spravato, not worth the money or the risk, watchdog says  Philly.comThe nasal spray for treatment-resistant depression was called overpriced. ICER also found an absence of long-term safety data.